S. M. Verma, B. K. Razdan and D. Sasmal, “3D-QSAR Study of 8-azabicyclo[3.2.1] Octane Analogs Antagonists of Cholinergic Receptor,” Bioorganic Medicinal Chemistry Letters, Vol. 19, No. 11, 2009, pp. 3108-3112. doi:10.1016/j.bmcl.2009.03.164

has been cited by the following article:

• TITLE: Synthesis and Study of Anti Parkinsonism activity of 8-azabicyclo [3.2.1] octane Analogs

  AUTHORS: Saurav M. Verma

  KEYWORDS: 8-azabicyclo [3.2.1] octane, Parkinsonism, Dopamine, Catatonia

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.2 No.2, March 31, 2011

  ABSTRACT: Parkinson's disease (PD) is a common neurodegenerative condition associated with the degeneration of dopaminergic neurons in the zona compacta of the substantia nigra. 3D QSAR study of 8-azabicyclo [3.2.1] octane analogs which serves as the pathfinder for the design of novel molecule for anti Parkinsonism. Five compounds of 8-azabicyclo [3.2.1] octane analogs are synthesized and the anti Parkinsonism activity and brain dopamine level were studied on albino mice. The anti Parkinsonian activity was determined by the effect of test compound A-F on drug induced catatonia using the method of Morpurgo. Atropine as well as compounds B and E significantly reduced the catatonic responses and tremors induced by chlorpromazine. The level of dopamine was measured after the administration of atropine and the test compounds in brain of mice. The study reveals that the compounds B and E have exhibited significant activity over atropine.